ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för raltegravir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

34 träffar

Bibliografisk träff 2021-08-01

Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir.

Kirkegaard-Klitbo DM, Thomsen MT, Gelpi M, Bendtsen F, Nielsen SD, Benfield T.

Clin Infect Dis · research support, non-u.s. gov't; journal article; observational study · DOI 10.1093/cid/ciab057

Bibliografisk träff 2021-08-01

Altered subcutaneous adipose tissue parameters after switching ART-controlled HIV+ patients to raltegravir/maraviroc.

Bastard JP, Pelloux V, Alili R, Fellahi S, Aron-Wisnewsky J, Capel E, Fève B, Assoumou L, Prifti E, Katlama C, Clément K, Capeau J.

AIDS · research support, non-u.s. gov't; journal article · DOI 10.1097/qad.0000000000002900

Bibliografisk träff 2021-07-01

Erratum to: Body Composition Changes after Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

Författaruppgift saknas

Clin Infect Dis · published erratum; correction · DOI 10.1093/cid/ciaa1740

Bibliografisk träff 2021-07-01

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).

Herrera C, Lwanga J, Lee M, Mantori S, Amara A, Else L, Penchala SD, Egan D, Challenger E, Dickinson L, Boffito M, Shattock R, Khoo S, Fox J.

J Antimicrob Chemother · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1093/jac/dkab136

Bibliografisk träff 2021-03-02

Raltegravir in patients with tuberculosis.

Pozniak A, Meintjes G.

Lancet Infect Dis · comment; journal article · DOI 10.1016/s1473-3099(20)30937-3

Bibliografisk träff 2021-03-01

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Krogstad P, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Brown E, Denson K, Graham B, Hovind L, Sise T, Teppler H, Mathiba SR, Fairlie L, Winckler JL, Slade G, Meyers T, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101 Team.

J Pediatric Infect Dis Soc · brief-report; clinical trial; journal article · DOI 10.1093/jpids/piaa039

Bibliografisk träff 2021-02-18

The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo.

Alburquerque-González B, Bernabé-García Á, Bernabé-García M, Ruiz-Sanz J, López-Calderón FF, Gonnelli L, Banci L, Peña-García J, Luque I, Nicolás FJ, Cayuela-Fuentes ML, Luchinat E, Pérez-Sánchez H, Montoro-García S, Conesa-Zamora P.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13040861

Bibliografisk träff 2021-02-02

Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir.

Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, Mirochnick M, Best BM, van den Anker JN, Dallmann A.

Clin Pharmacokinet · research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s40262-020-00977-w

Bibliografisk träff 2021-01-25

A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.

Bukkems VE, Post TM, Colbers AP, Burger DM, Svensson EM.

CPT Pharmacometrics Syst Pharmacol · comparative study; research-article; journal article · DOI 10.1002/psp4.12586

Bibliografisk träff 2021-01-01

Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.

Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C, ETRAL QD study group.

J Antimicrob Chemother · clinical trial; multicenter study; journal article · DOI 10.1093/jac/dkaa423

Bibliografisk träff 2020-12-01

Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.

Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.

J Acquir Immune Defic Syndr · research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0000000000002492

Bibliografisk träff 2020-12-01

Rate of DRESS Syndrome With Raltegravir and Role of the HLA-B*53: 01 Allele.

Lefebvre M, Walencik A, Allavena C, Billaud E, Kassi A, Cesbron A, Joyau C, Secher S, Ruellan AL, Raffi F, DRESS-RAL study group.

J Acquir Immune Defic Syndr · letter · DOI 10.1097/qai.0000000000002474

Bibliografisk träff 2020-11-01

Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.

Calza L, Colangeli V, Borderi M, Testi D, Granozzi B, Bon I, Re MC, Viale P.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkaa319

Bibliografisk träff 2020-10-16

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz.

Oster Y, Cohen MJ, Dresner-Pollak R, Szalat A, Elinav H.

Bone Rep · research-article; journal article · DOI 10.1016/j.bonr.2020.100727

Bibliografisk träff 2020-10-01

Low raltegravir transfer into the breastmilk of a woman living with HIV.

Feiterna-Sperling C, Bukkems VE, Teulen MJA, Colbers AP, PANNA network.

AIDS · research support, non-u.s. gov't; letter; journal article · DOI 10.1097/qad.0000000000002624

Bibliografisk träff 2020-09-21

Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.

Zheng Y, Hirt D, Delmas S, Lui G, Benaboud S, Lechedanec J, Tréluyer JM, Chenevier-Gobeaux C, Arezes E, Gelley A, Amri I, Urien S, Bouazza N, Foissac F, Warszawski J, Ghosn J.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1128/aac.00759-20

Bibliografisk träff 2019-08-27

Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.

Moreira FL, Marques MP, Duarte G, Lanchote VL.

J Pharm Biomed Anal · validation study; journal article · DOI 10.1016/j.jpba.2019.112838

Bibliografisk träff 2014-12-01

Raltegravir pharmacokinetics during pregnancy.

Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M, IMPAACT 1026s study team.

J Acquir Immune Defic Syndr · clinical trial; research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0000000000000318

Bibliografisk träff 2014-11-01

Raltegravir pharmacokinetics in neonates following maternal dosing.

Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.

J Acquir Immune Defic Syndr · clinical trial; research support, non-u.s. gov't; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0000000000000316

Bibliografisk träff 2014-08-11

A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.

Moss DM, Curley P, Shone A, Siccardi M, Owen A.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dku312

Bibliografisk träff 2014-08-01

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants.

Tsuchiya K, Hayashida T, Hamada A, Kato S, Oka S, Gatanaga H.

J Acquir Immune Defic Syndr · research support, non-u.s. gov't; journal article · DOI 10.1097/qai.0000000000000222

Bibliografisk träff 2014-08-01

Antiviral drug allergy.

Milpied-Homsi B, Moran EM, Phillips EJ.

Immunol Allergy Clin North Am · research-article; review; journal article · DOI 10.1016/j.iac.2014.04.011

Bibliografisk träff 2014-06-23

Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.

Stephan C, Baldauf HM, Barry J, Giordano FA, Bartholomae CC, Haberl A, Bickel M, Schmidt M, Laufs S, Kaderali L, Keppler OT.

J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dku213

Bibliografisk träff 2014-02-01

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Perry CM.

Paediatr Drugs · review; journal article · DOI 10.1007/s40272-013-0058-9

Bibliografisk träff 2014-01-10

Structural basis of Mos1 transposase inhibition by the anti-retroviral drug Raltegravir.

Wolkowicz UM, Morris ER, Robson M, Trubitsyna M, Richardson JM.

ACS Chem Biol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/cb400791u

Bibliografisk träff 2013-10-21

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.

Clin Infect Dis · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/cit696

Bibliografisk träff 2013-10-04

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).

Hernández-Novoa B, Moreno A, Pérez-Elías MJ, Quereda C, Dronda F, Casado JL, Madrid-Elena N, Aguilar M, Fumero E, Moltó J, Moreno S.

J Antimicrob Chemother · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1093/jac/dkt386

Bibliografisk träff 2010-10-28

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article · DOI 10.1073/pnas.1010246107

Bibliografisk träff 2010-01-31

Retroviral intasome assembly and inhibition of DNA strand transfer.

Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P.

Nature · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nature08784

Bibliografisk träff 2008-01-01

Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection.

Anker M, Corales RB.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.17.1.97